These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10030769)

  • 1. Hydroxyurea to inhibit human immunodeficiency virus-1 replication.
    Romanelli F; Pomeroy C; Smith KM
    Pharmacotherapy; 1999 Feb; 19(2):196-204. PubMed ID: 10030769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
    Lori F; Lisziewicz J
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of hydroxyurea in the treatment of HIV infection.
    Lori F; Kelly LM; Foli A; Lisziewicz J
    Expert Opin Drug Saf; 2004 Jul; 3(4):279-88. PubMed ID: 15268646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea for HIV infection.
    Zachary KC; Davis B
    AIDS Clin Care; 1998 Apr; 10(4):25-6, 32. PubMed ID: 11365149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea may enhance effectiveness of anti-HIV regimens presently in use.
    Murphy MJ
    Fac Notes (New Orleans La); 1998; 10(2):1-2. PubMed ID: 11365124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of human immunodeficiency virus type 1 inhibition by hydroxyurea.
    Lori F; Lisziewicz J
    J Biol Regul Homeost Agents; 1999; 13(3):176-80. PubMed ID: 10560752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection.
    Zala C; Rouleau D; Montaner JS
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S143-50. PubMed ID: 10860899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea - new observations.
    Proj Inf Perspect; 1998 Apr; (24):15-7. PubMed ID: 11365714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea in HIV therapy.
    HIV Hotline; 1998 Mar; 8(1):5-7. PubMed ID: 11365359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Hydroxyurea for real?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
    Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
    HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral drugs that target cellular proteins may play major roles in combating HIV resistance.
    Provencher VM; Coccaro E; Lacasse JJ; Schang LM
    Curr Pharm Des; 2004; 10(32):4081-101. PubMed ID: 15579090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.
    Lori F; Malykh A; Cara A; Sun D; Weinstein JN; Lisziewicz J; Gallo RC
    Science; 1994 Nov; 266(5186):801-5. PubMed ID: 7973634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutagenic outcome of combined antiviral drug treatment during human immunodeficiency virus type 1 replication.
    Mansky LM
    Virology; 2003 Mar; 307(1):116-21. PubMed ID: 12667819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea--ever more fascinating.
    Horn T
    Notes Undergr; 1998; (No 37):1-3, 9. PubMed ID: 11365816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of hydroxyurea in heavily pretreated patients with HIV infection.
    Hermans P; De Wit S; Sommereijns B; O'Doherty E; Clumeck N
    Antivir Ther; 1999; 4 Suppl 3():19-22. PubMed ID: 16021867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
    Montaner JS; Mo T; Raboud JM; Rae S; Alexander CS; Zala C; Rouleau D; Harrigan PR
    J Infect Dis; 2000 Feb; 181(2):729-32. PubMed ID: 10669364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication.
    Foli A; Maiocchi MA; Lisziewicz J; Lori F
    J Infect Dis; 2007 Nov; 196(9):1409-15. PubMed ID: 17922407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus.
    Johns DG; Gao WY
    Biochem Pharmacol; 1998 May; 55(10):1551-6. PubMed ID: 9633990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.